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Abstract: Dlx3 (distal-less homeobox 3) haploinsufficiency in mice has been shown to result
in restricted fetal growth and placental defects. We previously showed that maternal choline
supplementation (4X versus 1X choline) in the Dlx3+/−mouse increased fetal and placental growth in
mid-gestation. The current study sought to test the hypothesis that prenatal choline would modulate
indicators of placenta function and development. Pregnant Dlx3+/− mice consuming 1X (control),
2X, or 4X choline from conception were sacrificed at embryonic (E) days E10.5, E12.5, E15.5, and E18.5,
and placentas and embryos were harvested. Data were analyzed separately for each gestational day
controlling for litter size, fetal genotype (except for models including only +/− pups), and fetal sex
(except when data were stratified by this variable). 4X choline tended to increase (p < 0.1) placental
labyrinth size at E10.5 and decrease (p < 0.05) placental apoptosis at E12.5. Choline supplementation
decreased (p < 0.05) expression of pro-angiogenic genes Eng (E10.5, E12.5, and E15.5), and Vegf (E12.5,
E15.5); and pro-inflammatory genes Il1b (at E15.5 and 18.5), Tnfα (at E12.5) and Nfκb (at E15.5) in a
fetal sex-dependent manner. These findings provide support for a modulatory effect of maternal
choline supplementation on biomarkers of placental function and development in a mouse model of
placental insufficiency.
Keywords: choline; Dlx3; placenta; placental insufficiency; inflammation; angiogenesis; apoptosis
1. Introduction
Abnormal placental development underlies many pathologies of pregnancy including
preeclampsia, intrauterine growth restriction (IUGR), and spontaneous abortion [1]. These conditions
have serious consequences for the mother and fetus, and few treatments are currently available for
their prevention or treatment.
Although the etiology of placental insufficiency is not fully understood, an imbalance of pro-
and anti-angiogenic and inflammatory factors may contribute to it [1,2]. The development of the
placenta requires extensive angiogenesis and vasculogenesis, and the maternal uterine spiral arteries
must be invaded and remodeled by extravillous trophoblasts to allow for increased blood flow
to the fetus [3]. This process requires adequate expression of angiogenic and remodeling genes
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including the vascular endothelial growth factor (VEGF) family. Inadequate trophoblast invasion
is a characteristic of many placental pathologies. When this process is incomplete, blood flow to
the placenta is compromised, and oxygen supply may be sporadic, leading to placental injury from
hypoxia/reoxygenation. Oxidative stress, excessive apoptosis, and inflammation result, compromising
trophoblast function and preventing efficient transfer of nutrients [4]. Anti-angiogenic factors in the
maternal circulation, including soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng),
may contribute to the pathogenesis of preeclampsia symptoms including hypertension and proteinuria,
and can be used as biomarkers or predictors of risk when measured in early gestation [5,6]. Together,
these dysregulated processes interact to contribute to the pathogenesis of placental disorders such as
preeclampsia and IUGR.
The essential nutrient choline is required for the synthesis of the neurotransmitter acetylcholine,
the membrane phospholipid phosphatidylcholine, and the methyl donor and osmolyte betaine [7].
These biomolecules have crucial roles in supporting pregnancy via their effects on cell growth, DNA
methylation, and signaling processes [8]. Choline has previously been shown to reduce levels of
sFlt-1 in a randomized dietary intervention trial of maternal choline supplementation during the third
trimester of pregnancy in healthy women [9]. Further, choline deficiency has been shown to increase
inflammation and apoptotic processes in a cell culture model of human placental trophoblasts [10];
meanwhile, supplementing the maternal diet with additional choline decreases biomarkers of both
processes in wildtype mouse placenta [11]. We, thus, hypothesized that choline supplementation
would be beneficial for pregnancies complicated by placental insufficiency.
Dlx3 (distal-less homeobox 3) haploinsufficiency in mice has been shown to result in restricted
fetal growth and placental defects [12]. This homeodomain-containing transcription factor is required
for the development of the maternal–fetal interface [13]. Placentas lacking one copy of this gene
display inadequate vascularization and abnormal development of the placental labyrinth [12], which
is the area of nutrient exchange between the mother and fetus. Heterozygous embryos are viable
but their placentas display abnormalities including impaired remodeling of maternal spiral arteries
as well as increased placental oxidative stress and apoptosis [12]. In mice that are homozygous null
for Dlx3, placental failure occurs between embryonic days 9.5–12.5 resulting in extremely restricted
fetal growth and subsequently death [13]. Notably, we have previously shown that maternal choline
supplementation (4X versus 1X choline) in Dlx3+/− dams increases fetal weights during mid-gestation
in wildtype, heterozygous, and null embryos [14]. Most important to this body of work is the evidence
supporting a role of DLX3 in human placental insufficiency (reviewed in Reference [15]).
In the present study, we sought to use the Dlx3+/− mouse model of placental insufficiency
to investigate the effects of maternal choline supplementation on biomarkers of placental function
and development across gestation. To accomplish these aims, we used tissue samples that were
previously collected from Dlx3+/− pregnant dams randomized to consume one of three levels of
choline intake [14].
2. Materials and Methods
2.1. Mice and Diets
All animal protocols and procedures used in this study were approved by the Institutional
Animal Care and Use Committees at Cornell University, and were conducted in accordance with
the Guide for the Care and Use of Laboratory Animals. Dlx3+/− mice were genotyped using tail
DNA with three-primer duplex PCR (Table S1). Primers were designed to amplify a wildtype band,
a knockout band, or both (indicating a heterozygote). Mice were housed in microisolator cages
(Ancare, Bellmore, NY, USA) in an environmentally-controlled room (22–25 ◦C and 70% humidity)
with a 12-hour light–dark cycle. During breeding, mice were given ad libitum access to commercial
rodent chow (Teklad, Madison, WI, USA) and water. Dlx3+/− females were mated with Dlx3+/−
males in a pair-wise manner, and their offspring were genotyped at time of weaning (3 weeks of age).
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Heterozygous pups were given ad libitum access to the 1X choline control diet containing 1.4 g choline
chloride/kg (Dyets #103345). Dlx3+/− female mice were then randomized five days before mating
with Dlx3+/− male mice and received either the 1X choline control diet, the 2X choline diet containing
2.8 g choline chloride/kg (Dyets #103346), or the 4X choline diet containing 5.6 g choline chloride/kg
(Dyets #103347); all provided ad libitum. Embryonic (E) day 0.5 was designated via the presence
of a vaginal plug. Pregnant mice were euthanized via carbon dioxide asphyxiation at four different
gestational time points: E10.5, E12.5, E15.5, and E18.5.
2.2. Tissue Collection and Processing
After pregnant dams were sacrificed, embryos and placentas were carefully dissected with
minimal decidual contamination and weighed. For approximately 1/3 of the litter, the implantation
site was fixed in 10% formalin for histological analyses after removal of the embryo for genotyping.
For the remaining placentas, at gestational time points E12.5, E15.5, and E18.5, placentas were bisected
across the chorionic plate; one half was stabilized in RNAlater for mRNA analysis, while the remaining
half was immediately frozen in liquid nitrogen and stored at −80 ◦C for metabolite analysis. Due to
the smaller tissue size, E10.5 placentas were designated for mRNA analysis or metabolite analysis,
alternately. Fetal DNA was extracted for Dlx3 genotyping and sex determination using a commercial
kit (Qiagen Inc., Germantown, MD, USA). Sex genotyping was performed using PCR for the Sry gene
with a commercial kit (Qiagen Inc., Germantown, MD, USA). Primers are listed in Table S1.
2.3. Quantitative Real-Time RT-PCR
RNA was extracted from placentas maintained in RNAlater using TRIzol reagent (Invitrogen,
Waltham, MA, USA). Two to three Dlx3 heterozygous placentas per dam were randomly selected
for extraction. RNA concentration and quality were assessed with a NanoDrop ND-1000 instrument
(Thermo Fisher Scientific, Waltham, MA, USA), and samples with an A260/A280 ratio above 1.8
were used for quantification. Reverse transcription was performed using the ImProm-II Reverse
Transcription System (Promega, Madison, WI, USA). Quantitative PCR was performed using SYBR®
Green in a Roche LightCycler480 (Roche, IN, USA). All primers for the targeted genes (Vegfa, Pgf, Eng,
Mmp14, Tnfα, NfκB, Il1b) were designed using NCBI Primer-BLAST (Table S1). Reaction conditions
were as follows: 95 ◦C for 5 min, followed by 40 cycles for 15 s at 95 ◦C, 30 s annealing (see Table S1
for annealing temperatures), and 30 s at 72 ◦C. PCR product specificity was monitored using melting
curve analysis at the end of the amplification cycles. Fold changes were calculated using the ∆Ct
method [16] normalized to the expression level of the housekeeping gene Tbp (TATA box binding
protein), which has previously been shown to be stable in placental tissue [17], and in response to
varying choline supply [18]. At E10.5, both wildtype and heterozygous placentas were used due to
limited tissue availability, and Dlx3 genotype was included in the statistical model. All qPCR analyses
were performed in triplicate.
2.4. LC-MS/MS
Concentrations of acetylcholine were measured in the placenta using LC-MS/MS according to
the method of Holm et al. [19] with modifications based on our equipment [20].
2.5. Placental Morphometry
Placental tissues fixed in 10% formalin were paraffin embedded and sectioned at 10 µm.
Immunohistochemistry was performed on formalin-fixed sections as described previously [21]. For the
analysis of maternal spiral artery areas, placental sections were incubated with smooth muscle actin
(SMA) antibody (1:50, DakoCytomatin, Glostrup, Denmark), followed by a secondary antibody. Slides
were imaged using an Aperio Scanscope (Vista, CA, USA). Maternal spiral arteries were manually
defined based on the staining location and the presence of non-nucleated red blood cells. Aperio
ImageScope software, version 102.0.7.5, was used to quantify the area. Data are presented as the ratio
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of artery luminal area to total arterial area. For the analysis of the placental labyrinth area, placental
sections were incubated with biotinylated GSL 1-isolectin B4 (1:100, Vector Laboratories, Burlingame,
CA, USA) and 3-amino-9-ethylcarbazole (AEC; Invitrogen, Carlsbad, CA, USA), and counterstained
with hematoxylin. Isolectin is a marker of endothelial cells and has been used previously to stain
vasculature in other mouse tissues. The placental labyrinth compartment was defined manually based
on staining location, and area was calculated using Aperio ImageScope software (Vista, CA, USA).
Data are expressed as mm2 of cross-sectional labyrinth area.
2.6. Placental Apoptosis
Placental apoptosis was assessed using the terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay. A commercial kit (Millipore, Billerica, MA, USA) was used according to
the manufacturer’s instructions. Sections were imaged using an Aperio ScanScope and the number
of TUNEL-positive cells was determined in the decidua and labyrinth by the average number of
TUNEL-positive cells in several randomly selected fields. Field sizes were as follows: for E10.5, five
fields of 250× 250 µm2; for E12.5, five fields of 350× 350 µm2; and for E15.5 and E18.5, ten fields of 500×
500 µm2.
2.7. Statistical Analysis
For all outcome variables, data were analyzed separately for each gestational day using a linear
mixed model. All statistical models included choline treatment as a fixed effect, and a maternal
identifier (ID) as a random effect. Litter size, fetal genotype (except for the gene expression outcomes
at E12.5, E15.5, and E18.5, which only included heterozygous pups), and fetal sex (except when the
data were stratified by fetal sex) were controlled for in the models as fixed effects. Normality of the
data was assessed by evaluating the distribution of residuals. Due to the hypothesis-driven nature of
the study and the relatively small sample sizes, corrections for multiple analyses were not performed
and statistical interactions were not assessed. Data are presented as means ± SEM. p ≤ 0.05 was
considered statistically significant and 0.05 < p < 0.10 was considered to indicate trends. All analyses
were performed using SPSS software, Version 23 (IBM, Chicago, IL, USA).
3. Results
We previously reported that maternal choline supplementation increased placental and fetal
weights at E10.5 in offspring of Dlx3+/− dams regardless of fetal genotype [14]. These data can also
be found in Table S2 which depicts embryo weight, placental weight, crown rump length, placental
efficiency, and litter size in Dlx3+/− dams in response to maternal choline intakes (1X control, 2X, and
4X) at E10.5, E12.5, E15.5, and E18.5.
3.1. Placental Morphometry
Because the Dlx3 model is associated with labyrinth abnormalities, we sought to determine
whether choline treatment increased placental weight by increasing the size of the labyrinth. At E10.5,
4X choline placentas had 73% larger labyrinth area versus 2X choline (p = 0.014), and tended to be
~46% larger than 1X control placentas (p = 0.092, Figure 1A and 1B). At E12.5 and E15.5, there were
no significant differences in labyrinth size by choline treatment. At E18.5, 2X placental labyrinths
were ~25% smaller compared to 1X controls (p = 0.037) and tended to be ~20% smaller than 4X choline
placentas (p = 0.081, Figure 1A).
3.2. Placental Apoptosis
We performed the terminal deoxynucleotidyl transferase dUTP nick end labeling assay (TUNEL)
to assess placental levels of apoptosis at all four gestational time points. At E10.5, choline treatment
tended to result in ~49% lower TUNEL scores (average # TUNEL-positive cells per field) in the 4X
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choline placentas (p = 0.053 versus 1X controls) (Figure 2A). At E12.5, 4X choline placentas had ~58%
lower TUNEL scores (p = 0.048 versus 1X controls) (Figure 2A,B). No differences in TUNEL score were
detected between choline treatment groups at E15.5 and E18.5 (Figure 2A).
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E12.5, E15.5, and E18.5 by maternal choline treatment (A). entative images of TUNEL staining at
E12.5 are shown in (B). Data were nalyzed using ixed linear models with choli reatment as a fixed
effect and maternal ID as a random effect. Litter ze, fetal genotype, and fetal sex were controlled for
in the models as fixed effects. Values are presented as mean ± SEM. Different letters denote significant
differences between means of the treatments at p ≤ 0.05. † denotes p < 0.1 versus 1X choline controls.
n = 7–15 placentas per treatment per time point. NS, nonsignificant.
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3.3. Placental Artery Remodeling
Because we had previously found an effect of maternal choline supplementation on spiral artery
remodeling in wildtype mice [11], we investigated whether it would have a similar function in a model
of placental insufficiency. We assessed the luminal ratio of maternal spiral arteries, defined as (luminal
area)/total arterial area. Luminal ratio did not differ by choline treatment or Dlx3 genotype at any
gestational time point.
3.4. Placental Expression of Angiogenic Genes
Because altered levels of pro-angiogenic factors have been implicated in the development
of preeclampsia and other pregnancy disorders, we measured mRNA expression of several key
modulators of placental angiogenesis throughout pregnancy in Dlx3+/− placentas (Figure 3A–D).
For this outcome, we stratified by fetal sex due to our previous findings showing effects of fetal sex on
angiogenic gene expression [11].
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Figure 3. Placental mRNA abundance of angiogenic genes at (A) E10.5, (B) E12.5, (C) E15.5,
and (D) E18.5 by maternal choline treatment. Data are expressed as the fold-change relative to the
housekeeping gene Tbp. Data were analyzed using mixed linear models with choline treatment as a
fixed effect and maternal ID as a random effect. Litter size and fetal genotype (for E10.5; heterozygous
pups were used for E12.5, E15.5, and E18.5) were controlled for in the models as fixed effects. Values
are presented as mean ± SEM. Different letters denote significant differences between means of the
treatments at p ≤ 0.05. n = 20 placentas per treatment per time point.
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At E10.5, expression of Eng was ~31% lower in the female 2X choline placentas versus 1X controls
(p = 0.029) (Figure 3A). No effects of choline treatment on Eng expression were detected for the male
placentas, nor did choline treatment alter Vegfa, Pgf, or Mmp14 expression at E10.5 in either sex.
At E12.5, 2X and 4X choline males had lower expression of Eng vs. 1X controls (~64% and
~43%, respectively, p = 0.005, 0.013) (Figure 3B). Similarly, male 2X choline placentas had ~44% lower
expression of Vegfa (p = 0.026 versus 1X) (Figure 3B). No significant effects of choline treatment on
these angiogenic factors were detected in females; nor did choline treatment influence Pgf or Mmp14
expression at E12.5.
At E15.5, expression of Eng in female placentas was ~38% lower in the 2X choline group (p = 0.002
vs. 1X). Similarly, 2X choline female placentas had ~17% lower expression of Vegfa vs. 1X controls
(p = 0.031) (Figure 3C). Expression of Mmp14 was ~42% lower in female 2X choline placentas (p = 0.019,
vs. 1X) and ~41% lower in 4X choline placentas (p = 0.015, vs. 1X) (Figure 3C). No effects of choline
treatment on these angiogenic factors were detected in males; nor did choline treatment influence Pgf
expression in either fetal sex at E15.5.
At E18.5, male placentas in the 2X choline group had ~35% higher expression of Vegfa versus 1X
controls and 4X choline groups (p = 0.011 and 0.01, respectively). Similarly, expression of Pgf tended to
be ~29% higher in 2X choline males versus 1X control males (p = 0.091) and was ~42% higher versus
4X choline (p = 0.091). Male 2X choline placentas also had ~62% higher expression of Mmp14 versus
1X placentas (p = 0.006) (Figure 3D). No effects of choline treatment on these angiogenic factors were
detected in females; nor did Eng expression differ by choline treatment at E18.5 in either fetal sex.
3.5. Placental Expression of Inflammatory Genes
Abnormal regulation of inflammation has been shown in various placental pathologies; therefore,
we also measured mRNA expression of several major inflammatory regulators in the Dlx3+/−
placentas (Figure 4A–C). Again, data were stratified by fetal sex due to our previous work showing
the strong effects of fetal sex on inflammatory processes [11].
At E10.5, there were no significant differences in Tnfα, Nfκb, or Il1b expression among choline
treatment groups. At E12.5, 2X choline male placentas had a lower expression of Tnfα (~57% versus
1X) and tended to have lower expression of Nfκb (~50%, p = 0.096 versus 1X) (Figure 4A). No effects of
choline treatment on these inflammatory genes were detected in females; nor did expression of Il1b
differ by treatment.
At E15.5, female 2X choline placentas had ~33% lower expression of Nfκb versus 1X controls
(p = 0.020). Expression of Il1b was ~36% lower in 2X choline placentas of both sexes versus 1X controls
(p = 0.034, Figure 4B), and also in males alone (p = 0.031).
At E18.5, expression of Il1b was ~32% lower in 4X choline pups of male and female placentas
combined (p = 0.02) (Figure 4C), a finding that did not reach statistically significant levels in either sex
alone. Female 4X choline placentas tended to have ~39% lower expression of Nfκb versus 1X control
females (p = 0.058) (Figure 4C). No differences in Tnfα expression were seen among choline groups at
E15.5 or E18.5.
3.6. Placental Acetylcholine
Because acetylcholine has been linked to angiogenic and inflammatory signaling in the
placenta [22,23], we measured concentrations of placental acetylcholine throughout gestation. At E12.5,
2X choline placentas had ~136% higher concentrations of acetylcholine versus 1X controls (p = 0.011),
and ~107% higher concentrations versus 4X choline placentas (p = 0.020). At E10.5, E15.5, and E18.5,
acetylcholine concentrations did not differ by choline treatment (Figure 5).
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4. Discussion
4.1. Maternal Choline Supplementation in the Dlx3+/− Pregnant Dam Increases Placental Labyrinth Size and
Decreases Placental Apoptosis in Mid-Gestation
Because we had previously reported a higher placental weight at E10.5 with maternal choline
supplementation in Dlx3+/− dams [14], we sought to determine whether this effect could be
explained by alterations in the size of the placental labyrinth or apoptosis levels. Development
of the labyrinth region, which facilitates nutrient transfer between mother and fetus, is defective in
Dlx3−/− animals [13]. At E10.5, a high dose of choline (4X the recommended intake) yielded a larger
labyrinth size compared to the 2X choline dose, and tended to yield a larger labyrinth size compared
to the 1X choline dose. Thus, an increase in surface area for nutrient transfer may have contributed
to the larger embryo weights we previously reported in offspring (both +/− and +/+) of Dlx3+/−
mothers whom received 4X choline supplementation [14].
An additional explanation for the larger placental weights could be through reductions in
apoptosis. For example, 4X (versus 1X) choline placentas had ~58% lower TUNEL scores at E12.5,
and a tendency for lower scores (49% lower) at E10.5. These findings concur with previous results
showing reductions in apoptosis with choline supplementation in human trophoblast cells [10] and in
placentas of wildtype mice [11]. Although apoptosis is required for normal placental development,
elevated levels of apoptosis have been reported in preeclamptic and IUGR placentas [24–26]. Notably,
the elevated levels of apoptosis in Dlx3+/− placentas had previously been rescued using a strong
antioxidant, TEMPOL [12]. Therefore, a reduction in placental apoptosis in mid-gestation via maternal
choline supplementation may have beneficial effects in reducing the risk of developing placental
complications later in gestation.
In a preliminary histological examination of spiral artery remodeling, we did not find evidence
that maternal choline supplementation altered arterial luminal area percentage in the Dlx3+/− mouse.
This is in contrast to our previous findings in wildtype dams, where 4X choline significantly increased
luminal area percentage at E10.5, E12.5, E15.5, and E18.5 [11]. It is possible that the pathological
phenotype of spiral artery remodeling in the Dlx3+/− dam was too severe to be ameliorated by
choline supplementation. However, due to the small size of our histology cohort, this finding should
be confirmed in a larger study.
Although prior work has shown that Dlx3 is required for normal placental morphogenesis (13)
and reduced Dlx3 gene dose results in elevated placental cell oxidative stress and apoptosis coincident
with altered vascular remodeling (12), we did not detect any differences in labyrinth size, apoptosis
levels, or spiral artery remodeling between Dlx3+/+ and Dlx3+/− placentas. We previously found
that Dlx3+/− fetuses had comparable weights, but a higher expression of growth factor genes versus
their Dlx3+/+ littermates when their mothers consumed a high-quality pregnancy diet [14], suggesting
that the Dlx3+/− placenta may activate compensatory mechanisms that lead to results similar to
wildtype placentas for certain outcomes.
4.2. Effects of Maternal Choline Supplementation on Placental Inflammatory and Angiogenic Gene Expression
Vary by Gestational Time Point and Fetal Sex
Inflammation and angiogenesis have been shown to be dysregulated in pregnancy complications
including preeclampsia, IUGR, and spontaneous abortion [1,27,28]. Because of this, we measured
placental mRNA expression of major modulators of these processes to determine whether choline can
influence their placental expression in the Dlx3+/− mouse.
Overall patterns seen included the tendency for pro-inflammatory and pro-angiogenic markers
to be downregulated in response to choline supplementation, with the 2X dose frequently having a
larger effect than that of 4X. For example, compared to 1X choline, 2X choline significantly reduced the
expression of the proinflammatory factors Tnfα, Nfκb, and Il1b at various gestational time points of
pregnancy; a finding that was not consistently observed with 4X choline. Previous studies have shown
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that choline deficiency increases the expression of pro-inflammatory cytokines in a human placental
trophoblast cell culture model [10], and that maternal choline supplementation reduces inflammatory
response in pregnant rats challenged with lipopolysaccharide [29]. The results seen in the current study
with a 2X choline dose provide additional support for a role of choline in mitigating inflammation,
and suggest that efforts to increase maternal choline intake may be a nutritional strategy to reduce
placental inflammation and improve pregnancy outcomes especially since less than ten percent of U.S.
pregnant women meet choline intake recommendations [30].
The weakening of the choline-induced anti-inflammatory effects with the 4X treatment may suggest
variability whereby maternal choline supplementation has an anti-inflammatory effect up to a certain
concentration, beyond which its effects are attenuated. Alternatively, a strong growth-promoting effect of
4X maternal choline supplementation was detected in these mice at E10.5 [14], which was followed by a
gradual slowing of growth such that only minor differences were detected in fetal weights in late gestation
(E18.5). Thus, the effects of 4X choline on inflammatory (and angiogenic) processes in the placenta may
have been weakened by compensatory mechanisms engaged to prevent exaggerated fetal growth.
We also observed downregulation of placental expression of the proangiogenic factor endoglin
with maternal choline supplementation at E10.5 and E15.5 in female placentas and at E12.5 in males.
These effects were mirrored by similar downregulation of proangiogenic Vegfa, which has been
shown to be elevated or decreased in preeclamptic patients depending on the study [31–33]. It is
possible that the larger labyrinth observed at E10.5 in the current study, combined with the superior
placenta efficiency observed previously in these mice [14], resulted in a decreased need for placental
angiogenesis, leading to a downregulation of pro-angiogenic factors.
Endoglin also serves as the precursor to soluble VEGF receptor endoglin (sEng), an anti-angiogenic
factor that prevents VEGF from acting on target tissues [5], and contributes to the development of
placental dysfunction. In the current study, expression of Mmp14, the matrix metalloproteinase that
cleaves endoglin into its pathogenic soluble form [34], was significantly lower at E15.5 in females with
choline supplementation, which is suggestive of decreased generation of sENG. In males, however,
placental expression of Mmp14 was higher at E18.5 with 2X choline supplementation, suggesting
greater generation of sENG. This putative increase in sENG in late gestation could have a beneficial
role in preventing preterm birth by blunting the parturition promoting effects of VEGF signaling
through PGF and VEGF [31,32], both of which also were upregulated at this time point.
The effects of maternal choline supplementation on placental gene expression were sex specific,
as previously reported in wildtype mouse pregnancy [11]. Differential expression of angiogenic
factors according to fetal sex has been reported in both normal [33] and preeclamptic [35] human
pregnancies. Although the mechanisms remain unclear, sex-specific differences in epigenetic regulation
and hormonal environment have been suggested to be contributing factors [36,37]. Our findings add to
the body of evidence demonstrating that fetal sex should be accounted for when examining placental
and fetal outcomes during pregnancy.
4.3. Placental Concentrations of Acetylcholine are Minimally Affected by Maternal Choline Supplementation
Because acetylcholine has been reported to play a role in angiogenic [23] and inflammatory [22]
signaling in the placenta, we hypothesized that choline may be modulating gene expression by
altering acetylcholine levels. Surprisingly, we did not detect an increase in placental acetylcholine
concentrations in response to maternal choline supplementation at E10.5, E15.5, or E18.5. At E12.5,
acetylcholine levels were higher in the 2X, but not 4X, choline group. The overall lack of effect of
maternal choline supplementation on placental acetylcholine concentrations could reflect rapid uptake
of the acetylcholine molecule by the developing fetus as we previously reported that 4X choline
increased acetylcholine concentrations in the fetal brain of wildtype mice [38].
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4.4. Strengths and Limitations
The study strengths include: (i) the use of a standardized diet and three choline intake levels; (ii)
the inclusion of four gestational time points, which allows for a dynamic view of the changes that
occur in the placenta throughout gestation; and (iii) the use of an animal model with a hemochorial
structure similar to the primate placenta. Nonetheless, several limitations should be noted. The small
sample size combined with the relatively high degree of variability for most of the outcome data
precluded our ability to assess the interactive effects of fetal genotype and fetal sex with choline
treatment. An additional limitation of the current study was the analyses of mRNA abundance
without concurrent analyses of proteins. Finally, our histological analyses were included as a
hypothesis-generating examination of choline’s effects in compromised pregnancies, and should
be confirmed in larger cohorts.
5. Conclusions
In conclusion, maternal choline supplementation modulated placental development and function
in a mouse model of placental insufficiency, providing some evidence that choline may be a useful
therapy during pregnancy to prevent or overcome development of placental disorders that impact
fetal and maternal health. Decreases in pro-inflammatory gene expression and placental apoptosis are
especially encouraging and align with previous results showing similar effects of choline in different
experimental models. Since many pregnant women do not currently meet the recommended intake
levels of choline [30], further research is warranted to investigate the effects of increased maternal
choline intake on human placental function.
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